Table 3—

Crude and adjusted relative risk(RR) of severe cataracts for the mean daily dose of inhaled (ICS) and nasal corticosteroid (NCS) in the 4-yr period prior to the index date

CasesControlsCrude RRAdjusted# RR (95% CI)
Subjects n1075443016
ICS dose μg·day−1372.7±493.9305.6±453.01.381.24 (1.18–1.31)
Range (mean) of ICS dose+ n
 0 (0)μg·day−13716174541.01.0 (reference)
 >0–500 (196)μg·day−13908153741.221.14 (1.08–1.20)
 >500–1000 (737)μg·day−1181363161.401.26 (1.17–1.35)
 >1000–1500 (1206)μg·day−186926731.601.37 (1.25–1.51)
 >1500–2000 (1701)μg·day−13559321.891.59 (1.39–1.83)
 >2000 (2489)μg·day−1932671.741.40 (1.09–1.79)
NCS dose μg·day−116.3±57.414.2±51.31.081.03 (0.99–1.07)
Range (mean) of NCS dose+ n
 0 (0)μg·day−18570350081.01.0 (reference)
 >0–100 (34)μg·day−1163261171.091.03 (0.97–1.09)
 >100–200 (142)μg·day−131211111.151.04 (0.92–1.19)
 >200 (317)μg·day−12407801.261.12 (0.96–1.30)
  • Data are presented as mean±sd or absolute values. CI: confidence interval. #: for all factors in table 1, as well as the cumulative dose of the other class of topical corticosteroids; : per additional 1,000 μg·day−1 ICS or 100 μg·day−1 NCS (beclomethasone equivalents); +: among controls in category in beclomethasone equivalents.